Business Wire

WA-KYMETA

26.10.2021 15:02:16 CEST | Business Wire | Press release

Share
Kymeta’s Successful Test Demonstrates the Potential to Deliver Private LTE or 5GNR into a Smartphone via Broadband Satellite

Kymeta (www.kymetacorp.com ), the communications company making mobile global, announced today the successful testing of private Long Term Evolution (LTE) small cell on Citizens Broadband Radio Service (CBRS), demonstrating a complete connectivity solution that provides users with more reliable and robust connectivity directly to their smartphone and CBRS capable devices.

The trial was performed at Kymeta headquarters with a Kymeta™ u8 terminal, an off-the-shelf core running on an ARM single board compute (SBC), and an Accelleran small cell. The system delivers a turnkey solution to enhance the user experience by combining a private LTE network with the Kymeta terminal for broadband backhaul. CBRS enables a private intranet for communications to users like first responder teams and features video, push-to-talk, voice, and messaging apps within the CBRS coverage area while reserving the backhaul capacity for internet communications. In addition to backhaul, the system includes a core at the edge, allowing users’ devices to be bridged together locally without routing traffic back to the network core.

“Kymeta is testing and driving future technology breakthroughs as we look forward into our roadmap,” said Lilac Muller, Ph.D., Vice President of Product Management at Kymeta. “Public safety, defense, and enterprise authenticated users will have more resiliency from a small cell that is as easy as scanning a QR code. Smartphones will interact with the hybrid satellite terminal and CBRS as a private LTE hub and have both satellite and cellular backhaul in one solution."

CBRS is a publicly available spectrum in the 3550-3700 MHz band (3.5 GHz band) designated by the Federal Communications Commission (FCC) in 2015 as a frequency for shared wireless, private broadband. It is divided among users into three tiers of authorization, including Incumbent Access users, Priority Access Licenses (PAL), and General Authorized Access (GAA).

The project's success in demonstrating private LTE small cell on CBRS to a standard smartphone, from a system integrated with the Kymeta u8 terminal, is a notable achievement in helping chart a path for future user connectivity strategies and further validates Kymeta's ability to develop future-proof solutions that satisfy the overwhelming demand for resilient mobile connectivity and improved user access.

About Kymeta

Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company's satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company's flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.

Kymeta is a privately held company based in Redmond, Washington.

For more information, visit kymetacorp.com .

About Accelleran

Founded in 2013 and headquartered in Antwerp, Belgium, Accelleran provides disruptive software, solutions and services for Open 4G and 5G RAN and vRAN. The company’s unique approach supports genuine cloud-native deployment of RAN software components on the edge, in the cloud or embedded in the RRU. Accelleran’s commitment to openness enables multi-vendor radio deployments and delivers open RAN data for AI-enabled network algorithms. With a strong track record as the cellular industry’s leading RAN design, test and integration team, Accelleran is the natural choice for carrier-grade, reliable, portable and performant Radio Access Network Solutions and Services across multiple markets such as Private Networks, Fixed Wireless, Public Mobile, Neutral Host and IoT. For further information about Accelleran, please visit our website www.accelleran.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/kymetacorp

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye